Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts by Zakrzewicz, Dariusz et al.
32. Loi P, Paulart F, Pajak B et al. The fate of dendritic cells in a mouse
model of liver ischemia/reperfusion injury. Transplant Proc 2004; 36:
1275–1279
33. Kim MG, Boo CS, Ko YS et al. Depletion of kidney CD11c+ F4/
80+ cells impairs the recovery process in ischaemia/reperfusion-
induced acute kidney injury. Nephrol Dial Transplant 2010; 25:
2908–2921
Received for publication: 29.4.10; Accepted in revised form: 13.7.10
Nephrol Dial Transplant (2011) 26: 124–135
doi: 10.1093/ndt/gfq392
Advance Access publication 19 July 2010
Dimethylarginine metabolism during acute and chronic rejection of rat
renal allografts
Dariusz Zakrzewicz
1,*, Anna Zakrzewicz
2,*, Sigrid Wilker
2, Rolf-Hasso Boedeker
3, Winfried Padberg
2,
Oliver Eickelberg
4 and Veronika Grau
2
1Department of Medicine II, University of Giessen Lung Center, Aulweg 123, D-35392 Giessen, Germany,
2Laboratory of
Experimental Surgery, Department of General and Thoracic Surgery, Justus-Liebig-University Giessen, Rudolf-Buchheim-Str. 7,
D-35385 Giessen, Germany,
3Institute for Medical Informatics, Section of Medical Statistics, Justus-Liebig-University Giessen,
Heinrich-Buff Ring 44, D-35392 Giessen, Germany and
4Comprehensive Pneumology Center, Ludwig-Maximilians-University,
Asklepios Hospital, and Helmholtz Zentrum München, Ingolstädter Landstr 1, D-85764 Neuherberg/München, Germany
Correspondence and offprint requests to: Veronika Grau; E-mail: veronika.grau@chiru.med.uni-giessen.de
*These authors contributed equally to this study.
Abstract
Background. Dimethylarginines are inhibitors of NO syn-
thesis and are involved in the pathogenesis of vascular dis-
eases. In this study, we ask the question if asymmetric
dimethylarginine (ADMA) and symmetric dimethylargi-
nine (SDMA) levels change during fatal and reversible
acute rejection, and contribute to the pathogenesis of
chronic vasculopathy.
Methods. The Dark Agouti to Lewis rat strain combin-
ation was used to investigate fatal acute rejection. Fischer
344 kidneys were transplanted to Lewis rats to study re-
versible acute rejection episode and the process of chronic
rejection. Isograft recipients and untreated Lewis rats were
used as controls. L-arginine derivatives were determined by
HPLC, and ADMA-metabolizing enzymes were studied by
quantitative RT–PCR and western blotting.
Results. Renal transplantation transiently increased di-
methylarginine levels independent of acute rejection.
ADMA plasma levelsdid not importantlydiffer between re-
cipients undergoing fatal or reversible acute rejection,
whereas SDMA was even lower in recipients of Fisher
344 grafts. In comparison to isograft recipients, ADMA
and SDMA levels were slightly elevated during reversible,
but not during the process of chronic rejection. Increased
dimethylarginine levels, however, did not block NO synthe-
sis. Interestingly, protein methylation, but not ADMA deg-
radation, was increased in allografts.
Conclusions. Our data do not support the concept that
renal allografts are protected from fatal rejection by di-
methylarginines. Dimethylarginines may play a role in trig-
gering chronic rejection, but a contribution to vascular
remodelling itself is improbable. In contrast, differential
arginine methylation of yet unknown proteins by PRMT1
may be involved in the pathogenesis of acute and chronic
rejection.
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Introduction
Dimethylarginines have moved into the spotlight of scien-
tific interest as endogenous inhibitors of nitric oxide syn-
thesis. They are potential mediators of endothelial
dysfunction, hypertension and vascular remodelling, and
seem to be involved in chronic kidney diseases [1–7].
NO synthesis involves cellular uptake of L-arginine (L-arg)
by y
+ transporters, which is inhibited by asymmetric di-
methylarginine (ADMA) and by symmetric dimethylargi-
nine (SDMA) [1,6]. These transporters are also needed for
renal L-arg absorption and contribute to the maintenance
of systemic L-arg levels. L-arg can be converted to NO and
citrulline by NOS [2].
Dimethylarginine metabolism is also of outstanding
interest in the context of transplantation, predominantly
because the NOS isoforms, endothelial NOS (eNOS) and
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roles in acute and chronic allograft rejection [8–14]. Acute
and chronic allograft rejection are linked to each other, as
acute rejection is an important clinical risk factor for the
development of chronic rejection [15] and experimental
evidence suggests that chronic rejection is irreversibly trig-
gered during acute rejection episodes [16]. An important
hallmark of chronic rejection of kidneys is the develop-
ment of allograft vasculopathy, a severe intimal hyperpla-
sia of renal arteries. The idea suggests itself that increased
levels of dimethylarginines may play a role in the patho-
genesis of these lesions. Indeed, clinical and experimental
data evidenced that dimethylarginines contribute to cardiac
allograft vasculopathy [17,18], which resembles vasculo-
pathy of renal allografts [19].
ADMA and SDMA are elevated in patients suffering
from renal disease [3,20–24]. Moreover, ADMA levels
correlate negatively with renal function, and positively
with mortality and cardiovascular complications [25]. In
patients undergoing dialysis, ADMA and SDMA are also
increased [23]. Transplantation reduces SDMA [26],
whereas its effect on ADMA is disputed [23,24,26,27].
ADMA synthesis starts with the methylation of protein
arginine residues by protein arginine methyltransferases
(PRMTs) [28], which catalyse the formation of mono-
methylarginine (MMA) from L-arg [29]. These enzymes
are classified into type I (PRMT1, PRMT3, PRMT4,
PRMT6 and PRMT8) and type II (PRMT5, PRMT7 and
FBXO10). Type I PRMTs produce ADMA, while type II
PRMTs produce SDMA [28]. After proteolytic degrad-
ation of methylated proteins, MMA, SDMA or ADMA
are released and in part cleared by renal excretion [30].
In addition, ADMA, but not SDMA, is degraded in the
liver, kidney, and other organs to citrulline and dimethyla-
mines by dimethylarginine dimethylaminohydrolases
(DDAH), DDAH1, and DDAH2 [31,32].
The purpose of this study is to answer two questions: (i)
do dimethylarginine levels change during fatal and revers-
ible acute allograft rejection, and (ii) do dimethylarginines
and their metabolism contribute to the pathogenesis of
chronic vasculopathy? Therefore, we investigate dimethy-
larginine metabolism during renal allograft rejection as
well as NOS expression and activity. An experimental
model of fatal acute rejection of rat renal allografts is com-
pared with a model for chronic allograft rejection, which
involves a reversible rejection episode: (i) kidney trans-
plantation in the fully allogenic, Dark Agouti (DA) to
Lewis (LEW) rat strain combination leads to acute graft
destruction 4–5 days post-transplantation. Graft recipients
are investigated on Day 4. (ii) Kidneys transplanted in the
Fischer 344 (F344) to LEW combination remain functional
for at least 6 months but undergo reversible acute rejection
around Day 9 [33], and develop allograft vasculopathy in
the long run [34]. Those recipients are investigated on Day
9 and during vascular remodelling on Day 42.
Materials and methods
Details of materials and methods used in these studies are given in the
online supplementary data.
Animal experiments
LEW (RT1
1), DA (RT1
av1) and F344 (RT1
1v1) male rats weighing 260–
300 g from Harlan Winkelmann (Borchen, Germany) were kept under
conventional conditions. Animals received humane care following the
current version of the German Law on the Protection of Animals and
the ‘Principles of Laboratory Animal Care’ by the National Society for
Medical Research as well as the NIH ‘Guide for the Care and Use of
Laboratory Animals’.
Kidneys were transplanted orthotopically to totally nephrectomized
LEW recipients as described [35,36]. DA or F344 rats were used as do-
nors for allogenic transplantation, and LEW rats for isogenic transplant-
ation. Total ischaemic times remained below 30 min. Recipients of DA
kidneys died 7.4 ± 0.7 days (mean ± SD, n = 10) after surgery, whereas
F344 grafts remained functional for at least 180 days. Untreated healthy
LEW rats served as controls.
On Day 4, 9 or 42 after transplantation, animals were anaesthetized
with 60 mg/kg sodium pentobarbital i.p. (Narcoren, Merial, Hallberg-
moos, Germany) and obtained 1000 IU/kg heparin i.v. (Ratiopharm,
Ulm, Germany). Blood was taken by heart puncture and centrifuged at
4750 g for 10 min, and plasma was stored at −20°C. To assess renal func-
tion, plasma creatinine and urea were measured. A detailed description of
the method is given in the online supplementary data. Pieces of kidneys
were snap-frozen and stored at −80°C.
Immunohistochemistry
Immunohistochemical detection of PRMT1, and identification of mono-
cytes and T cells were essentially performed as described [33,37].
Quantification of ADMA, SDMA and L-arg
Isolation of basic amino acids and derivatization were performed as
described [32,38]. ADMA, SDMA and L-arg plasma levels were deter-
mined by high-performance liquid chromatography (HPLC).
DDAH activity
DDAH activity in tissue extracts was measured by an HPLC-based method
[32].
Quantitative RT–PCR
Details on the reverse transcriptase reaction, quantitative RT–PCR and
primer sequences are available in the online supplementary data.
Immunoblotting
Protein extraction and immunoblotting were performed essentially as
described [32].
Quantification of nitrite/nitrate (NOx)
To estimate NO production, NOx was determined by the Griess reaction
[39].
Statistics
Statistical evaluation was performed to answer the following questions: (i)
do acute or chronic rejection change the location of the distribution of the
parameters of interest? Data from isograft recipients are compared with
allograft recipients at the same time after transplantation. (ii) Does the
location of the parameters differ among animals undergoing fatal acute
(Day 4, DA to LEW) and reversible acute rejection (Day 9 allografts,
F344 to LEW)? (iii) Does the location of the parameters change between
Day 9 and Day 42 after allogenic transplantation? (iv) Do isogenic trans-
plantation and recipient nephrectomy change the location of the distribu-
tion of the parameters of interest in comparison to untreated controls? For
this purpose, data from control animals were compared with isograft re-
cipients (Day 4, 9 and 42). The distribution of the observed data was de-
scribed by median, minimum and maximum. The hypothesis that there is
no difference between the groups of interest was tested using the non-
ADMA in renal allograft rejection 125Fig. 1. ADMA, SDMA and L-arg plasma concentration. ADMA (A), SDMA (B) and L-arg (C) were quantified by HPLC in the blood plasma from
healthy control rats (C, white), isograft recipients (iso, dotted), and allograft recipients of DA and F344 donors (allo, grey). Graft recipients were
investigated on Day (d) 4, 9 and 42 post-transplantation. Data are displayed as median (bar), 25–75 percentiles (box), and the highest and lowest
data point (whiskers); circles indicate data beyond 3 × standard deviation; P-values ≤0.05 and number of animals (n) used in the study are indicated.
126 D. Zakrzewicz et al.parametric exact Mann–Whitney U-test (SPSS software version 15). Data
were analysed in exploratory manner.
Results
Histopathology
Day 4 renal allografts (DA to LEW) were characterized by
severe perivascular and interstitial mononuclear infiltrates,
and isografts were almost unimpaired [36]. After trans-
plantation in the F344-to-LEW rat strain combination,
which results in chronic rejection in the long run, severe
but reversible acute rejection developed peaking around
Day 9 after surgery [33]. Day 9 histopathology resembled
Day4DA-to-LEWkidneys,andthe infiltratewaspredomin-
antly composed of macrophages and T cells (Supplementary
Figures 1–3). On Day 42 (F344 to LEW), the infiltrate was
reduced, and macrophages and T cells still surrounded
bloodvesselsandexhibitedapatchydistributionintherenal
interstitium (Supplementary Figures 1–3 ) .D a y9a n dD a y
42 isografts were almost normal (Supplementary Figures
1–3; see online supplementary material for a colour version
of these figures).
ADMA, SDMA and L-arg plasma levels
In healthy control rats, the ADMA concentration was 2.10
(1.78–2.21)μmol/L, similar to previously published obser-
vations [40,41]. In comparison to controls, ADMA levels
were increased in isograft recipients on Day 4 and 9 after
transplantation, but returned to control levels on Day 42
( F i g u r e1 A ) .P l a s m aA D M Al e v e l so fD a y9a l l o g r a f t
(F344) recipients were higher compared with Day 9 iso-
graft and Day 42 allograft recipients (Figure 1A).
On Day 4, plasma SDMA levels were increased in iso-
graft recipients compared with controls (Figure 1B). How-
ever, our data did not suggest that Day 4 allograft
recipients differ from isograft recipients. SDMA levels at-
tained control levels in Day 9 and 42 isograft recipients,
but were elevated in Day 9 F344 allograft recipients com-
pared with isograft recipients.
L-arg plasma levels tended to be lower 4 days after allo-
genic transplantation compared with isograft recipients
(P = 0.095) and with F344 allograft recipients on Day 9
(Figure 1C). L-arg/ADMA and the L-arg/SDMA ratios
are indicated in Table 1. L-arg/ADMA ratios as well as
L-arg/SDMA ratioswere decreased in plasma samples from
allograft recipients during fatal acute rejection compared
Table 2. Urea and creatinine concentration in the plasma of control rats and renal graft recipients
Median (min–max) (P-value), mg/dL
Urea Creatinine
Control 36 (30–41) (n = 5) 0.50 (0.40–0.50) (n =5 )
Iso, Day 4 49 (42–101) (0.008)
a (n = 5) 0.70 (0.60–1.00) (0.008)
a (n =5 )
Allo DA, Day 4 58 (53–565) (0.310)
b (n = 5) 0.90 (0.80–4.90) (0.151)
b (n =5 )
Iso, Day 9 57 (48–64) (0.008)
a (n = 5) 0.60 (0.50–0.70) (0.016)
a (n =5 )
Allo F344, Day 9 98 (77–108) (0.016)
b (0.286)
c (n = 4) 0.85 (0.80–1.00) (0.016)
b (0.556)
c (n =4 )
Iso, Day 42 39 (35–49) (0.151)
a (n = 5) 0.60 (0.60–0.70) (0.008)
a (n =5 )
Allo F344, Day 42 66 (59–178) (0.008)
b (0.286)
d (n = 5) 0.80 (0.70–1.40) (0.032)
b (0.413)
d (n =5 )
The number of animals (n) used in the study is indicated.
aIsograft recipient versus control.
bAllograft versus isograft.
cAllograft Day 4 versus allograft Day 9.
dAllograft Day 9 versus allograft Day 42.
Table 1. L-arg/ADMA, L-arg/SDMA, and ADMA/SDMA ratios in the plasma of control rats and renal graft recipients
Median (min–max) (P-value)
L-arg/ADMA L-arg/SDMA ADMA/SDMA
Control 201 (137–229) (n = 5) 548 (360–602) (n = 5) 2.6 (2.6–2.9) (n =5 )
Iso, Day 4 164 (110–178) (0.095)
a (n = 5) 265 (139–345) (0.008)
a (n = 5) 1.5 (1.1–2.0) (0.008)
a (n =5 )
Allo DA, Day 4 97 (93–113) (0.032)
b (n = 5) 104 (66–175) (0.032)
b (n = 5) 1.1 (0.6–1.5) (0.151)
b (n =5 )
Iso, Day 9 156 (144–177) (0.151)
a (n = 5) 592 (485–768) (0.286)
a (n = 5) 3.7 (3.1–4.6) (0.016)
a (n =5 )
Allo F344, Day 9 138 (123–149) (0.063)
b (0.016)
c (n = 4) 354 (267–389) (0.029)
b (0.016)
c (n = 4) 2.5 (2.1–2.6) (0.029)
b (0.016)
c (n =4 )
Iso, Day 42 174 (161–263) (0.730)
a (n = 4) 432 (385–653) (0.730)
a (n = 4) 2.4 (2.3–2.6) (0.008)
a (n =5 )
Allo F344, Day 42 138 (121–159) (0.016)
b (1.000)
d (n = 5) 322 (123–351) (0.016)
b (0.190)
d (n = 5) 2.1 (1.0–2.5) (0.095)
b (0.190)
d (n =5 )
The number of animals (n) used in the study is indicated.
aIsograft recipient versus control.
bAllograft versus isograft.
cAllograft Day 4 versus allograft Day 9.
dAllograft Day 9 versus allograft Day 42.
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of F344 allografts on Day 9 (Table 1).
Renal function
Plasmacreatinineandureaconcentrationswereincreasedin
allisograftrecipients,exceptinDay42allografts,compared
with untreated controls (Table 2). In comparison to isograft
recipients, both urea and creatinine levels were increased in
recipients of F344 kidneys on Day 9 and 42 (Table 2).
DDAH mRNA expression and activity
Quantitative RT–PCR did not confirm the assumption that
DDAH1 mRNA expression in renal tissue differs between
experimental groups (Figure 2A). In contrast, DDAH2
mRNA levels were lower in Day 4 allografts compared
with isografts (Figure 2B). Renal DDAH function was ana-
lysed in vitro (Figure 2C and D), and equally high rates of
ADMA degradation were observed in all experimental
groups (Figure 2C and D). As expected, SDMA was not
degraded (Figure 2C, lower panel).
PRMT1 protein expression
PRMT1 protein levels were examined by western blotting
(Figure 3A, C and E). In both models, kidney allografts
were characterized by an increase in PRMT1 expression,
compared with appropriate isografts (Figure 3B, D and
F). Of note, also Day 42 F344 allografts expressed higher
PRMT1 levels (Figure 3F).
Immunohistochemistry using the same antibodies to
PRMT1 was performed on renal isografts and allografts
(Figure 4, Supplementary Figures 2 and 3). PRMT1 immu-
noreactivity was ubiquitously seen in all renal grafts.
Besides a moderate cytoplasmic staining, a more cons-
picuous nuclear signal was present in numerous but not
all cells. Structures morphologically compatible with distal
tubules and collecting ducts as well as single glomerular
cells were strongly immunopositive. Additionally, intensely
stainedcellsweredetectedinperivascular regionsandinthe
renal interstitium of all allografts. Numerous macrophages
and T lymphocytes were detected in the same regions, sug-
gesting that these strongly PRMT1-positive cells belong to
the infiltrate (Figure 4, Supplementary Figures 2 and 3).
PRMT1-positive infiltrates were less abundant in Day 42
F344 allografts (Supplementary Figures 2 and 3).
Protein methylation in renal tissue
To estimate renal PRMT function, methylated proteins
were analysed by western blotting using antibodies to
dimethylarginine–glycine repeats [42] (Supplementary
Figure 4). Protein methylation increased during acute re-
jection. Most strikingly, in Day 42 allografts undergoing
chronicrejection,severalproteinsexhibitedimpairedmethyl-
ation.In addition, differences in the methylation of individ-
ual proteins were observed between control kidneys,
isografts and allografts (details are given in Supplementary
Tables 1–3).
Expression of iNOS and eNOS
Protein levels of iNOS and eNOS were examined by west-
ern blotting. As expected, iNOS was induced in DA allo-
grafts during fatal acute rejection (Figure 5A). No iNOS
was detected in Day 9 and 42 F344 grafts (Figure 5B and
C). In contrast, eNOS was equally expressed by Day 4 iso-
grafts and allografts (Figure 5D and E). A slight increase in
eNOS expression was detected in Day 9 isografts, which in
turn did not differ from Day 42 isografts (Figure 5F–I).
Tissue and plasma NOx
Our experiments did not detect differences in NOx plasma
concentrations between controls and all isograft recipients
(Figure 6A). During acute rejection, however, NOx levels
markedly increased in allograft recipients of both models
compared with isograft recipients (Figure 6A). As ex-
pected, NOx levels were lower in recipients of F344 grafts
compared with recipients of DA grafts. Our data suggest
that NOx returns to isograft recipient levels in F344 allo-
graft recipients on Day 42.
Also, NOx isograft tissue levels did not differ from con-
trols (Figure 6B). NOx levels increased in allografts under-
going fatal acute rejection (Figure 6B), but in Day 9 and 42
F344 kidneys, NOx levels were not elevated compared
with isografts (Figure 6B).
Discussion
The most important findings of this study are (i) shortly
after renal transplantation and recipient nephrectomy,
ADMA and SDMA are increased, even in the absence of
acute rejection. (ii) ADMA levels did not importantly dif-
fer between recipients undergoing fatal and reversible
acute rejection, whereas SDMA concentrations are lower
during reversible rejection. (iii) During reversible acute re-
jection preceding chronic allograft rejection, ADMA and
SDMA plasma levels are slightly elevated in comparison
with isograft recipient plasma. (iv) PRMT1 protein expres-
sionandfunctionareincreasedinDAandinF344allografts
compared with isografts, probably due to graft-infiltrating
leucocytes. (v) In spite of elevated systemic dimethylar-
ginine concentrations, NOS is at least partially functional.
Fig. 2. DDAH mRNA expression and activity in renal grafts. DDAH1 (A) and DDAH2 (B) mRNA expression were analysed by qRT–PCR. Data are
expressed as the ΔCt of PBGD as a house-keeping gene, and DDAH1 or DDAH2. Healthy control kidneys (C, white), isografts (iso, dotted), and
allografts of DA and F344 donors (allo, grey) were investigated on Day (d) 4, 9 and 42 post-transplantation. (C, D) For the measurement of DDAH
activity,excess amountsof ADMAandSDMAwereaddedtoproteinextractsform controlkidneys,isograftsandallografts,andincubatedfor 2hat37°C.
Thereafter, ADMA and SDMAwere measured by HPLC. (C) HPLC chromatograms of a typical experiment: the upper panel shows a sample before, and
the lower panel after incubation at 37°C. Note that in contrast to ADMA, SDMA is not degraded. (D) Quantification of ADMA degradation; circles
indicate data beyond 3 × standard deviation; P-values ≤0.05 and number of animals (n) used in the study are indicated. (A, B, D) Data are displayed
as median (bar), 25–75 percentiles (box), and the highest and lowest data point (whiskers).
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arginine levels and their metabolism are involved in the
pathogenesis of acute or chronic kidney rejection, only dif-
ferences between isograft and allograft recipients are
relevant(SupplementaryFigure5).Themoststrikingdiffer-
ences are seen for PRMT1 expression and protein arginine
methylation, which strongly increase in allograft recipients
during fatal and reversible acute rejection and slightly in-
crease during the process of vascular remodelling on Day
42. The resulting increased protein methylation, however,
does not consistently lead to elevated dimethylarginine le-
vels, which are only seen during reversible acute rejection.
Accordingly, increased dimethylarginine levels may be in-
volved both in reverting acute rejection and in triggering
chronic rejection in F344 to LEW allografts at Day 9. As
the changes in dimethylarginines are very small, it can,
Fig. 3. PRMT1 expression in renal tissue. Homogenates of healthy control kidneys (C, white), isografts (iso, dotted), and allografts of DA and F344
donors (allo, grey) were separated by SDS–polyacrylamide (12%) gel electrophoresis. PRMT1 expression was (A, C, E) analysed by western blotting
on Day (d) 4, 9 and 42 post-transplantation. The intensity of the resulting bands (B, D, F) was quantified by densitometry and divided by the values
obtained for the house-keeping protein GAPDH. The mean of the PRMT1/GAPDH ratio of the controls was set to 1, and each individual value
including the control values was calculated accordingly. Data are displayed as median (bar), 25–75 percentiles (box), and the highest and lowest
data point (whiskers); P-values ≤0.05 and number of animals (n) used in the study are indicated.
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vance. Further interventional studies would answer these
questions. Certainly, more studies are needed to under-
stand the relevance of the vigorous changes in PRMT1
expression and protein methylation during organ rejection.
Increased ADMA and SDMA levels like those seen early
after transplantation may interfere with the cellular uptake
of L-arg by impairing NOS activity and renal re-uptake of
L-arg [6]. During fatal but not during reversible acute re-
jection, systemic L-arg levels are reduced. As iNOS protein
is stronglyexpressedconcomitantly,probably more L-argis
consumed. Increased circulating ADMA inhibits NOS ac-
tivity directly [22]. However, this does not seem to happen
in our experimental setting: although dimethylarginine le-
vels are increased in Day 4 allograft recipients, NOx levels
are elevated in plasma and in graft tissue, suggesting that
iNOS is at least partially functional. Furthermore, on Day
9after allogenic transplantation, whenADMA levelsarein-
creasedincomparisontoDay42,plasmaandtissuelevelsof
NOx are in the same range.
Possibly, high L-arg levels enable NOS function in
spite of increased ADMA. It is indeed a matter of debate
whether modest changes in dimethylarginine levels
modulate NO production [43,44]. Previously, Cardonuel
et al. [43] demonstrated in vitro that the L-arg/dimethyl-
arginine ratio must at least decrease to 10 to elicit a physio-
logical effect, and experiments in vivo demonstrated that
elevated ADMA levels do not necessarily result in im-
paired NO production [45,46]. We observe L-arg/ADMA
and L-arg/SDMA ratios above 100, suggesting that NOS
is unimpaired. However, ADMA and SDMA may contri-
bute to acute renal allograft rejection by NOS-independent
mechanisms such as stimulation of monocyte adhesion
[5,47] and production of reactive oxygen species [5,48].
The modulation of systemic dimethylarginine levels
during acute rejection is a complex process (Supplemen-
tary Figure 5). Systemic dimethylarginine concentrations
are regulated by at least four variables: (i) renal function
[30], (ii) ADMA degradation by DDAHs [4], (iii) protein
methylation by PRMTs [29] and (iv) degradation of
methylated proteins [49].
(i) Renal dysfunction may contribute to increased di-
methylarginine levels in graft recipients, which are to-
tally nephrectomized resulting at least in a 50%
reduction of the functional renal mass. Graft function
is indeed impaired in all recipients, but as expected,
isograft function on Day 9 and 42 is superior to allo-
graft function. Clinical studies demonstrated that
ADMA and SDMA levels are elevated in patients with
renal disorders [23,24,50], and dimethylarginine levels
are known markers of renal function [1,51,52].
Fig. 4. Localizationof PRMT1inrenal isografts andallografts.Immunohistochemistry usingantibodiestoPRMT1,a CD68-likeantigen (macrophages),
and the β-chain of the α/β T-cell receptor (T lymphocytes) was performed on paraffin sections of renal isografts (iso), DA allografts (allo) on Day (d) 4
post-transplantation.Immunopositivestructureswerestainedinbrown,andthesectionswerelightlycounter-stainedwithhemalum.Arrowsarepointingto
small arteries. Note the strongly PRMT1-immunoreactive infiltrate consisting of macrophages and T lymphocytes in the perivascular region as well asi n
the interstitium of renal allografts. The micrograph is representative for at least three independent experiments.
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[32,53]. As ADMA is enzymatically degraded in
the kidney [54], we analysed DDAH expression and
function in graft tissue. DDAH2 mRNA slightly de-
creased during fatal acute rejection, which was, how-
ever, not reflected in DDAH function. In contrast,
early after ischaemia/reperfusioninjuryof rat kidneys,
total DDAH function is impaired [46]. Our data sug-
gest that DDAH function is restored within 4 days.
We conclude that changes in ADMA levels are not
due to impaired renal degradation. DDAH activity,
however, may change in other organs such as the liver.
(iii) PRMT1, the dominating enzyme resulting in asymme-
tric protein methylation [55], is increased in all allo-
grafts. Immunohistochemistry suggests that this is
due to infiltrating leucocytes expressing high PRMT1
levels. This notion is also supported by western blot
experiments revealing a much stronger expression of
PRMT1 in normal rat spleens compared with kidneys
(data not shown). Hence, increased PRMT1 expres-
Fig. 6. NOx concentration in plasma and renal tissue. Rat plasma (A) or renal tissue extracts (B) were subjected to Griess reaction. Untreated healthy
control rats (C, white), isograft recipients (iso, dotted) and allograft recipients of DA and F344 kidneys (allo, grey) were investigated. Plasma and grafts
were investigated on Day (d) 4, 9 and 42 post-transplantation. Data are displayed as median (bar), 25–75 percentiles (box), and the highest and lowest
data point (whiskers); circles indicate data beyond 3 × standard deviation; P-values ≤0.05 and number of animals (n) used in the study are indicated.
Fig. 5. NOS protein expression. Homogenates of healthy control kidneys (C, white), isografts (iso, dotted), and allografts of DA and F344 donors (allo,
grey) were separated by SDS–polyacrylamide (8%) gel electrophoresis. Grafts were investigated on Day (d) 4 (A, D), 9 (B, F) and 42 (C, H) post-
transplantation. Western blots were performed using specific antibodies to iNOS (A–C) and eNOS (D–H). The positive control for iNOS expression is a
Day 4 DA allograft (B, C). The intensity of the resulting bands was quantified by densitometry and divided by the values obtained for the house-keeping
protein GAPDH (E, G, I). The mean of the eNOS/GAPDH ratio of the controls was set to 1, and each individual value including the control values was
calculated accordingly (E, G, I). Data are displayed as median (bar), 25–75 percentiles (box), and the highest and lowest data point (whiskers); P-values
≤0.05 and number of animals (n) used in the study are indicated.
ADMA in renal allograft rejection 133sion in allografts may contribute to increased systemic
ADMA levels. Changes in renal PRMT1 expression,
however, cannot be responsible for increased ADMA
concentrations in Day 4 isograft recipients. In addition
to PRMT1, other enzymes involved in protein methy-
lation remain to be investigated. Changes in the
methylation of several yet unindentified proteins were
detected in western blots using antibodies binding to
dimethylarginine–glycine repeats [42]. Methylation of
proteins regulates their function [28], which is prob-
ably the most important role of PRMT. For instance,
cytokine gene expression by effector T lymphocytes
critically depends on methylation of the signalling
molecule NIP45 [56]. Interestingly, methylation of se-
veral proteins was almost absent in Day 42 allografts.
(iv) Dimethylarginines are released upon degradation of
methylated proteins [49]. It can be predicted that tis-
sue damage during surgery results in increased protein
degradation. Accordingly, ADMA and SDMA levels
are increased early after transplantation. To clarify
the impact of tissue damage on dimethylarginine le-
vels, an additional group of sham-operated animals
could be included. We refrained from these experi-
ments as the data of isograft recipients, which do
not develop nephropathy, suggest that the initial in-
crease in dimethylarginine levels is not responsible
for allograft nephropathy. Furthermore, allograft rejec-
tion should result in an increased turnover of leuco-
cytes, another mechanism which may increase
dimethylarginine levels.
Interestingly, ADMA and SDMA plasma levels, as well
as PRMT1 and eNOS protein concentrations, were in-
creased in isograft recipients in comparison to controls. Se-
veralfactors maycontribute to these differences:ischaemia/
reperfusion injury caused by transplantation [46], reduced
renal function due to total recipient nephrectomy or due to
renal growth induced by a reduction of the total renal mass
in recipient rats.
Inconclusion,ourdatadonotsupporttheconceptthatthe
fate of renal allografts during acute rejection is decided by
dimethylarginines. Dimethylarginines may play a role in
triggering chronic rejection, but a contribution to the
processofvascular remodellingitself isimprobable.Incon-
trast, differential arginine methylation by PRMT1 may be
involved in the pathogenesis of acute and chronic rejection.
Supplementary data
Supplementary data is available online at http://ndt.
oxfordjournals.org.
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